Physician profile
Daniel Wayne Schatz
NPI 1164717070
$4,561.22
in general payments reported to CMS, 2019-2025
32 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $385 · 2021: $443 · 2022: $364 · 2023: $770 · 2024: $821 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $815.98 | 2019-2025 | Farxiga, Airsupra, Saphnelo |
| Novo Nordisk INC | $654.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $566.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $291.86 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $285.32 | 2019-2025 | Qulipta, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.22 | 2020-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $222.39 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $189.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $150.91 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Pfizer INC. | $112.54 | 2020-2024 | |
| Ibsa Pharma INC. | $112.12 | 2021-2025 | Tirosint, Licart, Flector |
| Amarin Pharma, INC. | $105.09 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $96.76 | 2019-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $83.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $64.04 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $60.80 | 2019-2020 | |
| Radius Health, INC. | $57.47 | 2024-2025 | Tymlos |
| Gilead Sciences, INC. | $55.30 | 2019-2025 | |
| Inspire Medical Systems, INC. | $45.37 | 2023-2024 | Inspire |
| Dynavax Technologies Corporation | $44.96 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.52 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $29.84 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.07 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $21.48 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $20.99 | 2025 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $19.96 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.03 | 2023 | Livalo, Seglentis |
| Neos Therapeutics, Lp | $17.31 | 2024 | Adzenys Xr-Odt |
| Sumitomo Pharma America, INC. | $16.22 | 2024 | Gemtesa |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.